^
Association details:
| Biomarker: | MET exon 14 mutation |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | KC1036 (FLT3 inhibitor, VEGFR-2 inhibitor, Tyrosine kinase inhibitor, AXL inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
60P - Establishment and characterization of a novel lung adenocarcinoma cell line HX-JCJ harboring MET ex14 skipping mutation
Published date:
10/16/2023
Excerpt:
In this study, we have established a novel lung adenocarcinoma cell line that harbors MET exon14 skipping mutation....Drug screen showed that this cell line was extremely sensitive to KC1036 (IC50=4.8nm), which is a home-made small molecule inhibitor with strong anti-MET and anti-angiogensis activity.
